|
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 1222-1230.
Prepublished online as a Blood First Edition Paper on October 12, 2004; DOI 10.1182/blood-2004-03-0802.
Previous Article | Next Article 
Submitted March 4, 2004
Accepted September 11, 2004
Meis1-mediated apoptosis is caspase-dependent and can be suppressed by coexpression of HoxA9 in murine and human cell Lines
Peter J Wermuth and Arthur M Buchberg*
Department of Microbiology and Immunology, Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
* Corresponding author; email: buchberg{at}mail.jci.tju.edu.
Coexpression of the homeodomain protein Meis1 and either HoxA7 or HoxA9 is characteristic of many acute myelogenous leukemias. Although Meis1 can be overexpressed in bone marrow long-term repopulating cells, it is incapable of mediating their transformation. While overexpressing HoxA9 alone transforms murine bone marrow cells, concurrent Meis1 overexpression greatly accelerates oncogenesis. Meis1-HoxA9 cooperation suppresses several myeloid differentiation pathways. We now report that Meis1 overexpression strongly induces apoptosis in a variety of cell types in vitro via a caspase-dependent process. Meis1 requires a functional homeodomain and Pbx-interaction motif to induce apoptosis. Coexpressing HoxA9 with Meis1suppresses this apoptosis and provides protection from several apoptosis inducers. Pbx1, another Meis1 cofactor, also induces apoptosis; however, coexpressing HoxA9 is incapable of rescuing Pbx-mediated apoptosis. This resistance to apoptotic stimuli, coupled with the previously reported ability to suppress multiple myeloid differentiation pathways, would provide a strong selective advantage to Meis1-HoxA9 coexpressing cells, in vivo, leading to leukemogenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Meis and Hox: a mighty pair defeats apoptosis
- Takuro Nakamura
Blood 2005 105: 909-910.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
J. Faber, A. V. Krivtsov, M. C. Stubbs, R. Wright, T. N. Davis, M. van den Heuvel-Eibrink, C. M. Zwaan, A. L. Kung, and S. A. Armstrong
HOXA9 is required for survival in human MLL-rearranged acute leukemias
Blood,
March 12, 2009;
113(11):
2375 - 2385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Fiskus, M. Pranpat, M. Balasis, B. Herger, R. Rao, A. Chinnaiyan, P. Atadja, and K. Bhalla
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Mol. Cancer Ther.,
December 1, 2006;
5(12):
3096 - 3104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fischer, A. Oberthuer, B. Brors, Y. Kahlert, M. Skowron, H. Voth, P. Warnat, K. Ernestus, B. Hero, and F. Berthold
Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome
Clin. Cancer Res.,
September 1, 2006;
12(17):
5118 - 5128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thomas, A. Gessner, H.-P. Vornlocher, P. Hadwiger, J. Greil, and O. Heidenreich
Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells
Blood,
November 15, 2005;
106(10):
3559 - 3566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Lawrence and C. Largman
The HOX-MEIS connection in AML
Blood,
July 1, 2005;
106(1):
6 - 7.
[Full Text]
[PDF]
|
 |
|
|
|